BriaCell Therapeutics Corp. (BCTX)
Market Cap | 109.71M |
Revenue (ttm) | n/a |
Net Income (ttm) | -26.11M |
Shares Out | 15.52M |
EPS (ttm) | -1.68 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 135,582 |
Open | 6.83 |
Previous Close | 6.83 |
Day's Range | 6.83 - 7.25 |
52-Week Range | 4.06 - 12.09 |
Beta | 1.38 |
Analysts | Buy |
Price Target | 11.16 (+57.85%) |
Earnings Date | Mar 21, 2023 |
About BCTX
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is h... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for BCTX stock is "Buy." The 12-month stock price forecast is $11.16, which is an increase of 57.85% from the latest price.
News

BriaCell CEO Letter to Shareholders
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 24, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...

BriaCell to Investigate Alleged Illegal Trading of Public Securities
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 23, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...

BriaCell Announces Positive End of Phase II Meeting with the FDA for Bria-IMT™ Combination in Advanced Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia,, Jan. 18, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnol...

BriaCell Announces New Patent Issuance, Bria-OTS™ IND Timing Guidance, and Additional Clinical Sites to Boost Enrolment
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 10, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...

BriaCell Announces Positive Clinical and Quality of Life Data in Advanced Metastatic Breast Cancer at 2022 San Antonio Breast Cancer Symposium®
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 08, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...

IPA's Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement to Discover and Develop Anti-Cancer Antibodies
VICTORIA, British Columbia & VANCOUVER, British Columbia & PHILADELPHIA--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) ( “IPA”) (NASDAQ: IPA), an advanced biotherapeutic research and technolo...

BriaCell Reports Positive Breast Cancer Efficacy Data with Bria-IMT™ Immunotherapy Treatment at SITC Annual Meeting
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...

BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 21, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...

BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium® December 6th and 7th
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnol...

BriaCell Partners with Caris Life Sciences® to Expand Patient Outreach and Molecular Profiling
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnol...

BriaCell Announces Presentation at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnol...

BriaCell Secures License for a Promising Novel Anti-Cancer Agent
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 04, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...

BriaCell Partners with Waisman Biomanufacturing to Manufacture and Supply Prostate Cancer Immunotherapy
PHILADELPHIA and VANCOUVER, British Columbia, July 05, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...

BriaCell Enters Research Agreement to Identify Novel Targets for Cancer Treatment
PHILADELPHIA and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...

BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal
PHILADELPHIA and VANCOUVER, British Columbia, June 24, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...

Creatv Bio's LifeTracDx® Liquid Biopsy Predicts Response to New Line of Therapy for Metastatic Breast Cancer within 30 Days
ROCKVILLE, Md.--(BUSINESS WIRE)--Creatv Bio, Division of Creatv MicroTech, Inc., announced today the release of an abstract featuring the results of its LifeTracDx® blood test for predicting response ...

BriaCell Adds Additional Clinical Sites to Broaden Patient Access and Further Boost Enrollment
PHILADELPHIA and VANCOUVER, British Columbia, May 18, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolog...

Why Is BriaCell (BCTX) Stock Moving Today?
BriaCell Therapeutics (BCTX) stock is on the move Wednesday morning after getting Fast Track approval from the FDA for Bria-IMT. The post Why Is BriaCell (BCTX) Stock Moving Today?

Why BriaCell Therapeutics Stock Is Surging Today
BriaCell Therapeutics Corp (NASDAQ: BCTX) shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Fast Track status to Bria-IMT for the treatment ...

BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy
PHILADELPHIA and VANCOUVER, British Columbia, April 13, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnol...

BriaCell Presents Development Details of Bria-OTS™ Platform Technology at the American Association for Cancer Research (AACR) Annual Meeting 2022
PHILADELPHIA and VANCOUVER, British Columbia, April 12, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnol...

BriaCell advances preparatory work for new Bria-OTS™ breast cancer clinical trial
PHILADELPHIA and VANCOUVER, British Columbia, April 07, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnol...

BriaCell Appoints Leading Immunologist Dr. Alexander Kharazi to its Scientific Advisory Board
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...

BriaCell Appoints Renowned Oncologist, Giuseppe Del Priore, MD, MPH, as Chief Medical Officer
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 16, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolo...

BriaCell Therapeutics Corp. Announces Results of 2022 Annual and Special Meeting of Shareholders
NEW YORK and VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), is pleased to announce that all ...